Purpose The purpose of this study was to evaluate the eVect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted. Methods This was an open-labeled, Wxed-sequence study of bevacizumab with FOLFIRI (irinotecan, leucovorin, and infusional 5-Xuorouracil). Pharmacokinetic assessments were conducted in cycles 1 and 3. Results Forty-Wve subjects were enrolled. No diVerence in dose-normalized AUC 0-last for irinotecan and SN-38 between irinotecan administered alone or in combination with bevacizumab was identiWed. Leukopenia was associated with higher exposure to both irinotecan and SN-38. UGT1A1 polymorphisms were associated with variability in irinotecan PK. Gastrointestinal toxicity was associated with UGT1A6 genotype. No other associations between UGT1A genotypes and toxicity were detected. Conclusion Bevacizumab does not aVect irinotecan PK when administered concurrently. A variety of pharmacogenetic relationships may inXuence the pharmacokinetics of irinotecan and its toxicity.
Background
Bevacizumab (rhuMab VEGF, Avastin®, Genentech, Inc., South San Francisco) is a humanized antibody against vascular endothelial growth factor (VEGF) that blocks the binding of VEGF to its cell surface receptor, resulting in disruption of the angiogenic signaling cascade. Bevacizumab was Wrst approved by the United States Food and Drug Administration for the treatment of patients with advanced colorectal cancer based on a phase III study which compared bevacizumab in combination with IFL (irinotecan, bolus Xuorouracil, and leucovorin) to IFL alone. In this clinical trial, increases in the incidence of grade 3 or 4 diarrhea and leukopenia were observed in the bevacizumab-containing arm [11] . A limited sampling pharmacokinetic substudy performed on 123 patients enrolled in this study suggested that the addition of bevacizumab to IFL was associated with a 33% increase in the AUC 0-5 of SN-38 (the most active metabolite of irinotecan), and that this may have corresponded to higher levels of toxicity in patients receiving bevacizumab [8] . However, the PK substudy was not deWnitive because of the short sampling time for irinotecan and the large inter-subject variability. In order to formally address the issue of a potential pharmacokinetic interaction between bevacizumab and irinotecan, a controlled trial was undertaken. An exploratory pharmacogenetic study was also conducted, since the disposition of irinotecan is known to vary in a fashion partially dependent upon genetic variation in its metabolic pathways.
Irinotecan is a prodrug that is metabolized to its active form, SN-38, by carboxyesterases. SN-38 is subsequently inactivated via a glucuronidation process to SN-38 glucuronide (SN-38G). Inactivation of SN-38 is catalyzed by members of the uridine diphosphate glucuronosyltransferase 1A (UGT1A) and CYP3A4 systems [18] . Although the most commonly studied enzyme involved in the glucuronidation of SN-38 is UGT1A1, data have emerged for the roles of UGT1A7, UGT1A6, and UGT1A9 isoforms in the glucuronidation process [7, 14, 20, 34] .
Irinotecan pharmacokinetics show signiWcant interpatient variability. Recent data have been inconsistent regarding the role of UGT1A gene polymorphisms in mediating irinotecan toxicity [1, 3, 10, 12, 19, 21, 29] . This inconsistency is likely a function of the redundant aYnity of several UGT1A isoforms for SN-38 as well as the complex genetics of the UGT1A loci [3, 7, 18] . Several studies have indicated an association between low activity UGT1A1 alleles and increased neutropenia in patients treated with irinotecan [10, 12, 15, 19] . These Wndings led to an FDA recommendation that irinotecan dosing be lowered in patients homozygous for the low activity UGT1A1*28 allele [22] . However, few studies have evaluated the role of UGT1A polymorphisms in toxicity associated with the most commonly used irinotecan regimens in patients with colorectal cancer, i.e., irinotecan in combination with infusional 5-FU [30] .
The primary objective of this clinical trial was to formally investigate whether bevacizumab impacts the PK of irinotecan and SN-38 in a controlled, fully powered clinical trial. The commonly used FOLFIRI regimen (irinotecan, leucovorin, and bolus 5-FU followed by continuous infusion 5-FU over 46 h) [31] was selected as the platform for this study. Furthermore, we also explored the association of pharmacogenetic parameters of the UGT1A gene on the pharmacokinetic and toxicity proWles of irinotecan in this regimen.
Methods

Study design and patient eligibility
This was a phase I, open-label, Wxed sequence clinical trial conducted at three study centers utilizing the combination of 5-Xuorouracil, leucovorin, irinotecan, and bevacizumab. This clinical trial was approved by the institutional review board at each participating institution. All the patients provided written informed consent prior to entering both the study and the substudy.
Eligible patients had histologically conWrmed advanced solid tumors for which treatment with FOLFIRI plus bevacizumab was medically reasonable. Other selection criteria included age >18 years; ECOG performance status 0 or 1; adequate organ function including absolute neutrophil count ¸1500/ul, platelets ¸100,000/ul, total bilirubin ·1.5 mg/dl, AST <3£ upper limit of normal or <5£ upper limit of normal if liver metastases, creatinine ·2.0 mg/dl, hemoglobin ¸9 g/dl, and International Normalized Ratio (INR) ·1.5 unless receiving warfarin sodium.
Patients were excluded if they had received prior irinotecan or bevacizumab therapy; prior monoclonal antibody therapy; major surgical procedure or chemotherapy within 28 days prior to Day 0; or history of serious systemic disease including myocardial infarction or stroke within 6 months prior to Day 0, unstable angina, clinically signiWcant peripheral vascular disease, blood pressure >150/ 100 mmHg, or New York Heart Association grade II or greater congestive heart failure; CNS or brain metastases; lung carcinoma; urine protein/creatinine ratio ¸1.0 at screening; evidence of bleeding diatheses or coagulopathy; non-healing wound, ulcer, or bone fracture; or history of abdominal Wstula, gastrointestinal perforation, or intraabdominal abscess within 26 days prior to Day 0. The use of concomitant drugs including St. John's Wart, phenytoin, valproic acid, phenobarbital, cyclosporine, indinavir, nelWnavir, ritonavir, saquinovir, Xuconazole, itraconazole, or ketoconazole within 30 days prior to Day 0 was prohibited.
Treatment
Patients were treated with the FOLFIRI regimen as described by Tournigand et al. [31] (irinotecan 180 mg/m 2 IV administered over 90 min plus racemic leucovorin 400 mg/m 2 IV administered over 2 h, followed by 5-Xuorouracil 400 mg/m 2 IV bolus followed by 2400 mg/m 2 continuous IV infusion over 46 h every 2 weeks). Bevacizumab 5 mg/kg IV was administered over 30 min every 2 weeks, with the initial two doses given over 90 and 60 min, respectively. During cycle 1, patients received FOLFIRI alone on Day 0 and bevacizumab was administered on Day 2 after the last irinotecan PK sample was drawn. In subsequent cycles, bevacizumab was administered prior to FOLFIRI on the same day. Dose adjustments were made based on interval toxicities. The primary study period during which PK sampling was obtained was cycles 1 through 3. Subjects deriving beneWt from treatment with FOLFIRI plus bevacizumab could continue treatment every 2 weeks for a period of up to 2 years. Treatment discontinuation was permitted for disease progression, adverse events, discretion of treating physician, or subject withdrawal of consent.
Clinical assessments
Toxicity was graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3 [5] during cycles 1-3. All the subjects who received any study treatment were included in the safety analysis population. In order to assess the risk of toxicity after the Wrst cycle and its relationship to UGT1A polymorphism, the highest grade of toxicity during cycle 1 and over cycles 1-3 was evaluated with respect to genotype.
Pharmacokinetic assessments
For irinotecan and SN-38 PK, plasma samples were collected at the following time points on the Wrst day of cycles 1 and 3: prior to the start of the irinotecan infusion, 45 and 90 min after the initiation of irinotecan infusion, and postinfusion at 5, 10, 15, and 30 min and 1, 2, 4, 6, 8, 10, 24, 30, and 48 h. For bevacizumab peak or trough concentrations, serum samples were collected prior to and 10 min after the completion of the bevacizumab infusion during cycles 1, 2, and 3. Plasma samples were analyzed for irinotecan, SN-38, and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin (APC) by mass spectrometry with minimum quantiWable concentrations of 5.0, 1.0, and 2.0 ng/ml, respectively (Cedra Corp., Austin). Serum bevacizumab concentrations were measured by enzymelinked immunosorbent assay (Genentech, Inc., South San Francisco) with a minimum quantiWable concentration of 78 ng/ml.
Non-compartmental analysis methods were used to calculate PK parameters using concentrations at or above the limit of quantiWcation. PK parameters were determined for irinotecan, SN-38, SN-38G, and APC, and included AUC 0-last and AUC 0-inWnity , clearance, maximum concentration (C max ), time to maximum concentration (T max ), mean residence time, terminal half-life, and steady-state volume of distribution. Calculations were performed using WinNonlin, Version 4.1 (Pharsight Corporation, Mountain View, California).
UGT1A genotyping
Before cycle 1, an optional blood sample was collected from patients for germline analysis of genes relevant to irinotecan metabolism. Blood was collected in Vacutainer tubes and stored at¡70°C until processing. BuVy coat from whole blood was used to isolate genomic DNA via automation on the Gentra AutoPure LS using the PureGene chemistry. Candidate genes were selected based on known involvement in the metabolic pathway of irinotecan and functionally signiWcant genetic polymorphisms.
For UGT1A1 genotyping, a 119-bp region of the promoter was ampliWed by PCR using Jumpstart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma) in a 25-l reaction with 20-30 ng genomic DNA as the template. The PCR and pyrosequencing were carried out using primers and thermal cycling conditions according to the methods described by Saeki et al. [27] . This method allows for discrimination of the n = 5, 6, 7, and 8 TATA repeat that deWnes the common UGT1A1 alleles. UGT1A1*28 is deWned as n = 7 TATA repeats and is associated with lower UGT1A1 enzyme activity than the n = 6 TATA repeat UGT1A1*1 allele. For UGT1A6 T19G (S7A, rs6759893), A541G (T181A, rs2070959), A552C (R184S, rs1105879) polymorphisms, a 238-bp fragment containing the codon 7 SNP and a 215-bp fragment containing the codon 181 and 184 SNPs were ampliWed by PCR using Jumpstart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma) in a 25 l reaction with 20-30 ng genomic DNA as the template. PCR and pyrosequencing were carried out using primers and thermal cycling conditions according to the methods described by Carlini et al. [3] . UGT1A7 and UGT1A9 SNPs were genotyped by BigDye® Terminator cycle sequencing on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems) according to the methods of Carlini et al. [3] . The PCR reactions contained Jumpstart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma) and 20-30-ng genomic DNA template in a 25-l volume.
The UGT1A isoforms were binned in cases where enzymatic activity could be predicted. UGT1A6 and UGT1A7 genotypes were binned according to predicted enzyme activity [3, 20, 34] . For UGT1A6, genotype bins were categorized as high, moderate, low, and unknown enzyme activity. UGT1A7 genotype bins were categorized as high or low enzyme activity. Genotype bins for UGT1A6 and UGT1A7 were used for the pharmacogenetic substudy analyses. Genotypes for UGT1A1 and UGT1A9 were utilized for the pharmacogenetic substudy analyses, as there are little data to support the prediction of UGT1A9 activity from genotype. (Table 1) Toxicity categories assessed were diarrhea; leukopenia; gastrointestinal toxicity (including mucositis, nausea, vomiting, diarrhea, and dehydration); and other toxicities including fever, asthenia, cardiovascular, respiratory, nervous system, skin, constipation, anorexia, and abdominal pain. Toxicity data were available during cycles 1-3, while pharmacokinetic data were available for cycles 1 and 3 of FOLFIRI plus bevacizumab treatment.
Statistical methods
Statistical analyses to determine drug-drug interaction were based on the FDA recommendations for in vivo drug metabolism/drug interaction studies [32] and pre-speciWed prior to study initiation and assaying of serum samples. Analyses utilized AUC 0-last , which was normalized to a dose of 1 mg/ m 2 of administered irinotecan. The primary statistical analysis was the estimation of the geometric mean ratio (GMR) of the AUC 0-last in the presence of bevacizumab (cycle 3) to the AUC 0-last in the absence of bevacizumab (cycle 1). ConWdence intervals (CIs) were calculated for GMRs by calculating the diVerence between the log-transformed AUC 0-last using the t-distribution and then back-transformed to the ratio scale. The 90% CI for the GMR of irinotecan was compared with pre-speciWed bounds (0.8, 1.25) while the 90% CI for the GMR of SN-38 was compared with pre-speciWed bounds (0.7, 1.43) due to a larger intrasubject variability [32] . The equivalence hypotheses compare the pharmacokinetics of irinotecan with and without bevacizumab. If the 90% CI of the GMR for irinotecan was completely contained within pre-speciWed (0.8, 1.25), and the 90% CI of the GMR for SN-38 was completely contained within pre-speciWed (0.7, 1.43), and the point estimate of the GMR for SN-38 was within pre-speciWed (0.8, 1.25), then it would be concluded that bevacizumab had no signiWcant eVect on the pharmacokinetics of irinotecan.
Pharmacogenomic analyses with regard to UGT1A were exploratory. The method of Guo and Thompson [9] was used to test for Hardy-Weinberg equilibrium. One-sided Jonckheere-Terpstra tests were used to assess the association of discrete toxicity categories and pharmacokinetic measures. The Kruskal-Wallis [28] test was used to assess the relation of genotype (UGT1A1 and UGT1A9), or genotype bins (UGT1A6 and UGT1A7), to pharmacokinetic measures of C max and AUC of irinotecan and SN-38. Permutation tests [28] were used to assess the signiWcance of associations in sparse contingency table chi-squared tables of toxicity versus genotype or enzyme activity bins.
Results
Demographics and disease characteristics
Forty-Wve subjects were enrolled between January 4, 2005 and October 26, 2005 at three institutions. Patient characteristics included a median age 55.0 years (range 30-74), 64% male, 92% Caucasian, and ECOG performance status 0 (53%) and 1 (47%). The most common primary tumor types included esophagus (12) , ovary (9), and pancreas (5). The most frequent sites of metastases included the liver (44%) and lymph nodes (42%).
Pharmacokinetic and drug-drug interaction analysis
The drug-drug interaction PK analysis population included 36 subjects. This population excluded the six subjects who did not complete all the three cycles of treatment, two patients who did not have adequate PK sample to support AUC calculation, and one patient who did not receive bevacizumab in cycle 3. Twenty-two out of the 36 patients (61%) received prior systemic therapy with four having two or more prior regimens. Twenty-seven out of 36 patients experienced a dose delay and/or reduction of irinotecan due to diarrhea and/or leukopenia. Dose-normalized concentration-time proWles for irinotecan and SN-38 concentrations are displayed in Figs. 1 and  2 , respectively. The C max , T max , elimination half lives, clearance, steady-state volumes of distribution, and pharmacokinetic properties of irinotecan and its metabolites for cycles 1 and 3 are listed in Table 2 . These parameters are consistent with previous reports [4, 6, 23] . The GMR of the AUC 0-last in the presence of bevacizumab (at cycle 3) to the AUC 0-last in the absence of bevacizumab (at cycle 1) was calculated for both irinotecan and SN-38 and is presented in Table 2 together with the 90% CI. The GMR point estimates and 90% CIs are within pre-speciWed boundaries, which indicate that the presence of bevacizumab does not alter the pharmacokinetics of irinotecan.
Serum samples were collected pre-and post-infusion at cycles 1 and 3 to conWrm bevacizumab exposure. Table 3 summarizes bevacizumab peak and trough concentrations for the analysis population. Bevacizumab peak concentrations in this trial were lower than those observed in previous studies, perhaps due to diVerences in sampling times and inherent diYculty in reliably measuring peak (1) concentrations, while the trough concentrations were consistent with previous experience [17] .
Adverse events
Thirty-nine patients received all the scheduled FOLFIRI treatments at full or reduced doses, while 38 patients received FOLFIRI and bevacizumab at full or reduced doses. Forty-three patients had at least one adverse event during cycles 1-3, with four patients having adverse events leading to study discontinuation. The most common toxicities overall were nausea (60%), vomiting (20%), diarrhea (51%), leukopenia (51%), sweating (24%), and dehydration (16%). The most common grade 3 or 4 adverse events were leukopenia (38%), dehydration (9%), asthenia (4%), nausea (4%), and diarrhea (4%). Twenty-two patients had a grade 3 or 4 adverse event, with 17 out of 45 (38%) patients having grade 3 or 4 leukopenia. Pharmacogenetic and pharmacodynamic substudy Thirty-nine patients consented to participation in the pharmacogenetic substudy. Genotyping was unsuccessful in two patients, one patient had incomplete adverse event reporting, and eight patients were not evaluable for pharmacokinetics. Therefore, 37 patients had genotyping, 29 had genotyping and PK, 30 had PK and toxicity data, and 36 had genotyping and toxicity data. Out of the patients who consented to the substudy, 30 were included in the drugdrug interaction PK analysis population. All the genotypes appeared to follow Hardy-Weinberg equilibrium, including UGT1A1*28.
Within the substudy population, leukopenia during cycle 1 was associated with the C max of SN-38 during cycle 1 (P = 0.049), as well as the AUCs of irinotecan (P = 0.007) and its active metabolite SN-38 (P = 0.016). These relationships were conWrmed when the highest grade of leukopenia across cycles 1-3 was considered. In contrast, there was no association between diarrhea and the pharmacokinetic parameters of irinotecan (P = 0.21 for C max and P = 0.26 for AUC 0-last ) or its active metabolite (P = 0.87 for C max SN38 and P = 0.71 for AUC 0-last SN38). Other toxicities such as mucositis, nausea, vomiting, and dehydration were also not associated with C max or AUC 0-last of irinotecan, SN-38, or SN-38G. This Wnding was consistent when considering cycle 1 alone and combined cycles 1-3.
We conducted exploratory analyses of the association between genotype and PK parameters. As shown in Table 4 , there was an association between UGT1A1 genotype and mean C max and AUC 0-last of irinotecan and SN-38. UGT1A7 genotype bin trended toward an association with mean C max of SN-38 and mean AUC 0-last of SN-38. However, this may be largely attributed to the impact of higher Table 2 Irinotecan, SN-38, APC, and SN-38G plasma pharmacokinetic parameters Volume of distribution: for irinotecan, it is the steady-state volume of distribution (mL/m2); for SN-38, APC, and SN-38G, it is WinNonlin output that is a composite of metabolite volume of distribution, clearance, and fraction metabolized For each irinotecan metabolite (SN-38, APC, and SN-38G), clearance is apparent clearance, which is CL/fm, where fm is the fraction of the parent drug that is metabolized to that metabolite No associations were detected between UGT1A genotypes or genotype bins and diarrhea, leukopenia, or combined GI toxicities during cycle 1. No association between leukopenia across cycles 1-3 and UGT1A genotypes or genotype bins was detected. However, an association between UGT1A6 genotype bin and overall gastrointestinal toxicity was observed across cycles 1-3 (P = 0.028), with greater toxicity seen in patients with low and moderate activity genotypes. UGT1A7 genotype bin was not associated with toxicity.
Discussion
The data we present demonstrate that the pharmacokinetics of irinotecan was not altered by the presence of bevacizumab. This study was undertaken as follow-up of an exploratory PK analysis conducted within the bevacizumab colorectal cancer licensing trial that suggested elevated SN-38 exposure in the presence of bevacizumab [8] . We employed a single-arm design in which each patient served as his/her own control, and pharmacokinetic analysis covered four to Wve irinotecan half-lives. These features allowed for adequate capture of the concentration-time curves to estimate all the parameters necessary to deWnitively address the potential interaction between bevacizumab and irinotecan.
In order to control for irinotecan dose reduction between cycles, dose normalization of the PK parameters were utilized to avoid an imbalanced comparison between cycle 1 and cycle 3 irinotecan and SN-38 PK. Irinotecan and SN-38 pharmacokinetics are linear in the doses administered in this study [4, 26] . Bevacizumab trough concentrations were consistent with previous observations, indicating that patients in this study received clinically relevant exposure to bevacizumab.
We used this formal PK study as an opportunity to explore the interactions between irinotecan-metabolizing enzyme polymorphisms, pharmacokinetics, and toxicity. Consistent with other reports, irinotecan and SN-38 exposure were associated with leukopenia in our study [4, 14, 23, 24, 33] . Notably, GI toxicities such as diarrhea had no association with PK parameters. This lack of association between plasma PK and diarrhea suggests that plasma levels of irinotecan and SN-38 may not be the only driving force behind the development of diarrhea. The contribution of local intestinal exposure to SN-38 via hydrolysis of SN-38G by glucuronidases in the microXora may also play a role in the variable severity of irinotecan-induced diarrhea [16, 25] . However, this lack of association is complicated by the low incidence of severe diarrhea observed in this small patient population.
Recent data have raised the question of whether UGT1A genotype should be used to help guide irinotecan dosing [29, 30] . In particular, the UGT1A1*28 allele has been associated with the development of neutropenia following irinotecan therapy, and these data lead to an FDA recommendation for a reduced initial dose in patients homozygous for this allele [12, 13, 15] . In a recent study of 250 patients with metastatic colorectal cancer receiving FOLFIRI as Wrst-line treatment, the UGT1A1*28 allele was associated with a higher risk of grade 3 or 4 neutropenia during the Wrst cycle, but this association was not observed when the entire treatment period was considered [30] . We sought to establish a mechanism for this observation by assessing genetics, PK, and toxicity in the same patients. Although we were able to conWrm a relationship between UGT1A1 polymorphisms and SN-38 exposure, we did not Wnd an association between genotype and toxicity, particularly leukopenia. We had also previously reported a lack of association between UGT1A1 genotype and toxicity in patients treated with irinotecan plus capecitabine [3] . In that previous study, UGT1A7 and UGT1A9 low activity genotypes were associated with reduced gastrointestinal toxicity. Consistent with our Wndings, other studies also did not support an association of UGT1A1 genotype with diarrhea [14, 19, 29, 30] . A signiWcant limitation of our analysis of UGT1A pharmacogenomics is the small sample size of this study, and the potential bias in enrolling patients with the UGT1A1*28 allele associated with restricting the eligibility criteria to a total bilirubin ·1.5 mg/dl. Although we did observe Hardy-Weinberg equilibrium among the enrolled subjects, this criterion may have biased the study against enrolling those most vulnerable to SN-38-related toxicities. Our results must therefore be viewed as exploratory.
We observed an association between UGT1A6 enzymatic activity level and gastrointestinal toxicities across all the three cycles. In a previous study, we did not Wnd an association between UGT1A6 genotype and toxicity in patients receiving capecitabine plus irinotecan [2] . This discordance between studies may relate to diVerences in the chemotherapy regimens investigated, patient populations, or small sample sizes of the studies conducted. Clearly, further study in this area is necessary to dissect the interplay between various UGT1A alleles, haplotypes, and toxicities with particular chemotherapy combinations and schedules.
In conclusion, bevacizumab does not impact the pharmacokinetics of irinotecan administered in the FOLFIRI regimen. Our exploratory pharmacogenetic analyses conWrmed the relationship between UGT1A1 low-activity alleles and increased SN-38 exposure, but not toxicity. Controversy remains regarding UGT1A1 genotyping for patients initiating irinotecan, and our exploratory pharmacogenomic substudy results suggest the need for larger trials to explore the contribution of other UGT1A isoforms on pharmacokinetics and toxicity of irinotecan.
